
Firm recognized for its ability to observe therapy response with its Signatera™ MRD exam


AUSTIN, Texas, March 28, 2022 /PRNewswire/ — Natera Inc. (NASDAQ: NTRA), a international leader in cell-absolutely free DNA tests, has been named to Quick Firm’s annual record of the World’s Most Revolutionary Corporations for 2022.




Natera rated sixth in the Wellness category and was identified for its customized and tumor-educated molecular residual illness (MRD) test, Signatera, and its potential to observe immunotherapy response. Two key scientific tests1,2 have demonstrated Signatera’s potential to forecast which individuals, across a wide assortment of cancer forms, are most probable to benefit from immunotherapy. As of November 2021, Medicare addresses the serial use of Signatera for pan-cancer immunotherapy checking.


“This recognition is a testomony to the effects Signatera has manufactured on the lives of folks dwelling with most cancers and our pursuit to remodel cancer care with customized MRD screening,” mentioned Steve Chapman, CEO of Natera. “We continue being steadfast in our dedication to developing revolutionary products and solutions and solutions that aid advise folks about their health and are honored to have manufactured this prestigious list.”


The World’s Most Progressive Corporations is Quick Firm’s signature franchise and 1 of its most remarkably predicted editorial endeavours each individual 12 months, delivering both a snapshot and a street map for the long term of innovation across the most dynamic sectors of the economic climate.


About Natera


Natera™ is a world-wide leader in cell-totally free DNA screening, dedicated to oncology, women’s wellness, and organ wellness. We goal to make personalized genetic testing and diagnostics element of the normal of care to shield overall health, and advise earlier, additional targeted interventions that assistance direct to extended, more healthy lives. Natera’s assessments are validated by extra than 100 peer-reviewed publications that demonstrate substantial precision. Natera operates ISO 13485-certified and CAP-accredited laboratories certified below the Clinical Laboratory Enhancement Amendments (CLIA) in Austin, Texas and San Carlos, California. For additional data, visit www.natera.com.


About Quick Company


Rapidly Enterprise is the only media model absolutely devoted to the critical intersection of organization, innovation, and style and design, engaging the most influential leaders, businesses, and thinkers on the future of business enterprise. Headquartered in New York City, Rapid Firm is revealed by Mansueto Ventures LLC, along with our sister publication Inc., and can be discovered on the internet at www.fastcompany.com.


Ahead-On the lookout Statements


All statements other than statements of historic specifics contained in this push release are forward-searching statements and are not a illustration that Natera’s ideas, estimates, or anticipations will be obtained. These forward-wanting statements stand for Natera’s anticipations as of the date of this press release, and Natera disclaims any obligation to update the forward-hunting statements. These ahead-hunting statements are subject to known and unfamiliar risks and uncertainties that may cause precise outcomes to vary materially, like with regard to our endeavours to develop and commercialize new product or service offerings, whether or not the success of clinical or other reports will help the use of our products choices, the affect of success of this kind of reports, our anticipations of the reliability, accuracy and general performance of our checks, or of the rewards of our assessments and product offerings to individuals, companies and payers. Further challenges and uncertainties are mentioned in better element in “Possibility Variables” in Natera’s current filings on Sorts 10-K and 10-Q and in other filings Natera makes with the SEC from time to time. These files are obtainable at www.natera.com/buyers and www.sec.gov.


Contacts


Trader Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350

Media: Kate Stabrawa, Communications, Natera, Inc., [email protected]


References


- 
- Powles T, Assaf ZJ, Davarpanah N, et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Mother nature. 2021595(7867):432-437.
- Bratman SV, Yang SYC, Iafolla MAJ, et al. Personalised circulating tumor DNA examination as a predictive biomarker in good tumor clients handled with pembrolizumab. Nat Most cancers. 20201(9):873-881.








See unique content to obtain multimedia:https://www.prnewswire.com/information-releases/natera-listed-as-one particular-of-worlds-most-revolutionary-wellbeing-organizations-by-quick-enterprise-301511427.html


Source Natera, Inc.